ImmuCell Corporation (NASDAQ:ICCC - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.36 and traded as high as $7.16. ImmuCell shares last traded at $6.88, with a volume of 14,227 shares traded.
ImmuCell Price Performance
The company has a debt-to-equity ratio of 0.30, a current ratio of 4.12 and a quick ratio of 2.21. The firm has a 50-day moving average of $5.91 and a 200-day moving average of $5.36. The stock has a market cap of $62.20 million, a PE ratio of -98.27 and a beta of 0.30.
ImmuCell (NASDAQ:ICCC - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter. ImmuCell had a negative return on equity of 1.02% and a negative net margin of 1.00%. The firm had revenue of $8.07 million during the quarter.
Institutional Trading of ImmuCell
Several institutional investors have recently made changes to their positions in ICCC. Dauntless Investment Group LLC purchased a new position in ImmuCell during the 4th quarter valued at approximately $676,000. Citadel Advisors LLC purchased a new position in ImmuCell during the 4th quarter valued at approximately $149,000. Northern Trust Corp grew its holdings in ImmuCell by 51.0% during the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after buying an additional 14,982 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its holdings in ImmuCell by 100.0% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company's stock valued at $125,000 after buying an additional 12,178 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in ImmuCell by 13.9% during the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock valued at $332,000 after buying an additional 7,878 shares in the last quarter. Hedge funds and other institutional investors own 13.47% of the company's stock.
ImmuCell Company Profile
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
